Clinical Trials: A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Share this article:
Sponsor and Collaborators
Amgen

Contact
Amgen Call Center
866-572-6436

Principal Investigator
MD Amgen

ClinicalTrials.gov Identifier
NCT00770848
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Prostate Cancer Clinical Trials

Clinical Trial: Tumor TARGET Prostate Cancer

Clinical trial focusing on tumor TARGET prostate cancer. Tumor TARGET Prostate Cancer

Clinical Trial: Two-Dose Level Evaluation of NX-1207 for the Treatment of Low ...

Clinical trial focusing on NX-1207. Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Clinical Trial: Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate ...

Clinical trial focusing on multi-radiotracer PER/MR. Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer